scholarly journals 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response

2018 ◽  
Vol 201 ◽  
pp. 315-323 ◽  
Author(s):  
Stefan Leucht ◽  
Anna Chaimani ◽  
Claudia Leucht ◽  
Maximilian Huhn ◽  
Dimitris Mavridis ◽  
...  
Keyword(s):  
Antipsychotic Drug ◽  
Placebo Response ◽  
Drug Trials ◽  
Acute Schizophrenia ◽  
Meta Regression

scholarly journals Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis

2019 ◽  
Vol 44 (11) ◽  
pp. 1955-1966 ◽  
Author(s):  
Stefan Leucht ◽  
Anna Chaimani ◽  
Dimitris Mavridis ◽  
Claudia Leucht ◽  
Maximilian Huhn ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Antipsychotic Drug ◽  
Acute Phase ◽  
Drug Response ◽  
Placebo Response ◽  
Drug Trials ◽  
Meta Regression ◽  
Meta Regression Analysis

Increasing Placebo Response in Antipsychotic Drug Trials: Let’s Stop the Vicious Circle

2013 ◽  
Vol 170 (11) ◽  
pp. 1232-1234 ◽  
Author(s):  
Stefan Leucht ◽  
Stephan Heres ◽  
John M. Davis
Keyword(s):  
Antipsychotic Drug ◽  
Placebo Response ◽  
Vicious Circle ◽  
Drug Trials

Placebo response in antidepressant drug trials

1994 ◽  
Vol 9 (3) ◽  
pp. 115-118 ◽  
Author(s):  
M Beneke ◽  
W Rasmus ◽  
J Fritze
Keyword(s):  
Frequency Analysis ◽  
Low Dose ◽  
Antidepressant Drug ◽  
Placebo Response ◽  
Response Patterns ◽  
Relative Efficacy ◽  
Drug Trials ◽  
Double Blind ◽  
Pooled Data ◽  
Blind Trials

SummaryResponse patterns derived from dichotomized (0/1) weekly CGI ratings conducted in antidepressant drug trials (Quitkin et al, 1984) were compared with those found in the pooled data from several randomized double-blind trials comparing the relative efficacy and tolerability low-dose flupenthixol im with that of three trieyclics (amitriptyline sr, imipramine, doxepine). Using the configurational frequency analysis (Krauth and Lienert, 1973), the postulated patterns could be rediscovered in our data apart from “early onset persistent patterns” which were less frequent in Quitkin et al's (1984) drug data. However, apart from this finding no “typical” patterns in terms of drug- or placebo-dependent response patterns could be detected in either the flupenthixol or Quitkin et al's (1984) data. It is concluded that there is little empirical evidence for the assumption of placebo- or drug related change- or response patterns. Moreover, theoretical aspects do not support the usefulness of such concepts.

scholarly journals Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression

2020 ◽  
Vol 10 (4) ◽  
pp. 385-394 ◽  
Author(s):  
Rocio Roji ◽  
Patrick Stone ◽  
Federico Ricciardi ◽  
Bridget Candy
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Placebo Response ◽  
Risk Of Bias ◽  
Small Samples ◽  
Contributing Factors ◽  
Cancer Related Fatigue ◽  
Study Results ◽  
Meta Regression ◽  
Multiple Drugs

BackgroundCancer-related fatigue (CRF) is one of the most distressing symptoms experienced by patients. There is no gold standard treatment, although multiple drugs have been tested with little evidence of efficacy. Randomised controlled trials (RCTs) of these drugs have commented on the existence or size of the placebo response (PR). The objective of this systematic review was to establish the magnitude of the PR in RCTs of drugs to relieve CRF and to identify contributing factors.MethodRCTs were included in which the objective was to treat CRF. A meta-analysis was conducted using the standardised mean change (SMC) between baseline and final measurement in the placebo group. To explore factors that may be associated with the PR (eg, population or drug), a meta-regression was undertaken. Risk of bias was assessed using the revised Cochrane tool.ResultsFrom 3916 citations, 30 relevant RCTs were identified. All had limitations that increased their risk of bias. The pooled SMC in reduction in fatigue status in placebo groups was −0.23 (95% confidence intervals −0.42 to −0.04). None of the variables analysed in the meta-regression were statistically significant related to PR.ConclusionThere is some evidence, based on trials with small samples, that the PR in trials testing drugs for CRF is non-trivial in size and statistically significant. We recommend that researchers planning drug studies in CRF should consider implementing alternative trial designs to better account for PR and decrease impact on the study results.

Pretrial Medication Bias in Randomized Antipsychotic Drug Trials

2007 ◽  
Vol 164 (8) ◽  
pp. 1266-1266 ◽  
Author(s):  
STEFAN LEUCHT ◽  
STEPHAN HERES ◽  
JOHANNES HAMANN ◽  
WERNER KISSLING
Keyword(s):  
Antipsychotic Drug ◽  
Drug Trials
Sign in / Sign up

Export Citation Format

Share Document